You are here: Industry Insights > NICE

News List

NICE approves first long-acting jab for HIV to replace daily pills PharmaTimes
November 22, 2021
NICE has published draft guidance recommending the first long-acting injectable treatment for HIV-1 infection in adults, offering an alternative to adults living with HIV who have to take daily antiretroviral drugs.
NICE approves first long-acting injectable HIV-1 treatment EuropeanPharmaceuticalReview
November 19, 2021
The National Institute of Health and Care Excellence (NICE) has announced the publication of draft guidance recommending cabotegravir, the first long-acting injectable treatment for HIV-1 infection in adults.
NICE recommend dapagliflozin for treating chronic kidney disease EuropeanPharmaceuticalReview
November 09, 2021
The National Institute for Health and Care Excellence (NICE) has recommended dapagliflozin as an option for treating certain individuals with chronic kidney disease (CKD) in new draft guidance.
NICE recommends AstraZeneca’s dapagliflozin to treat chronic kidney disease Pharmaceutical-Business-Review
November 09, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s dapagliflozin as a treatment for people with chronic kidney disease (CKD).
NICE recommends Eli Lilly’s breast cancer drug Verzenios pharmatimes
August 13, 2021
Draft NICE guidance has recommended Eli Lilly’s twice-daily pill Verzenios (abemaciclib) as an option for adults with a type of breast cancer called hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.
bluebird bio re-evaluates gene therapy strategy in ‘untenable’ European market pharmatimes
August 12, 2021
Among a second quarter results announcement full with setbacks, bluebird bio has revealed that it will exit the European market after failing to secure access for its gene therapy with various governments.
NICE pens two-year collaboration with the Academic Health Science Network pharmatimes
August 06, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has announced a new collaboration with the Academic Health Science Network, focused on supporting the NHS in adopting evidence-based healthcare.
NICE approves cost-comparison fast-track appraisal pilot europeanpharmaceuticalreview
August 03, 2021
A new approach to the cost-comparison fast-track appraisal process is being piloted this summer for the review of low-risk appraisals.
UCB’s bimekizumab issued NICE recommendation for severe plaque psoriasis pharmatimes
August 03, 2021
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD), recommending UCB’s bimekizumab as an option for the treatment of adults with severe plaque psoriasis.
NICE publishes ‘rapid’ guideline on rare blood clots associated with COVID-19 jab pharmatimes
August 02, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has published a new guideline of the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) associated with COVID-19 vaccination.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page